Viking Therapeutics, Inc.VKTXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +11.22% | +8.32% | +1.58% | +1.27% | +2.39% |
| Weighted Average Shares Diluted Growth | +11.22% | +8.32% | +1.58% | +1.27% | +2.39% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +146.50% | -10.39% | -12.57% | -21.16% | -21.20% |
| Book Value per Share Growth | +127.17% | -16.28% | -14.97% | -22.75% | -29.10% |
| Debt Growth | -11.19% | -15.33% | -20.18% | -38.87% | -87.76% |
| R&D Expense Growth | +51.14% | +71.73% | +153.07% | +294.79% | +395.24% |
| SG&A Expenses Growth | +73.64% | +41.20% | +40.21% | -37.49% | -26.04% |